+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 68 Pages
  • June 2020
  • Region: Asia Pacific
  • Mordor Intelligence
  • ID: 5120179
The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 2.5% during the forecast period. The major factors driving the growth of the market in the Asia region is due to growing awareness about Uterine diseases and their available therapies, increasing health care expenditure and innovation in drug development, and subsequent technological advancements.

According to Cancer Australia, estimated that in 2016, there were about 527 deaths from uterine cancer in Australia. In 2019, it was estimated at around 562 deaths. In addition, it also stated that the risk of a female dying from uterine cancer will be 1 in 205.

Furthermore, governments are provoking awareness programs in certain Asia-Pacific regions. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly over the forecast period.

Key Market Trends

Endometrial Adenocarcinoma is Expected to Witness Highest Growth Over the Forecast Period in the Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market

The major factors driving the growth of the segment is due to the growing burden of endometrial adenocarcinoma. For instance, as per Cancer Australia, in 2019, it is estimated that the age-standardized incidence rate of uterine cancer was about 20 cases per 100,000 females in Australia. The incidence rate for uterine cancer was expected to increase with age, peaking at age group 65-69.

Furthermore, as per the Journal of Gynecological Oncology 2020, endometrial cancer is a major gynecologic malignancy with the highest rate among patients with gynecologic malignant tumors in Japan. In Japan, the age-adjusted mortality rate of endometrial cancer was 2.0 in 2017. In addition, in Australia, there were about 3,115 (4.7%) new cases of uterine cancer diagnosed in 2019 as per Cancer Australia. Thus, owing to the above factors the segment is expected to show growth in the coming years.

Competitive Landscape

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is consolidated competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share. Some of the companies involved in the market are Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, GlaxoSmithKline Plc and Novartis AG.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
4.2.2 Increasing Health Care Expenditure
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
4.3 Market Restraints
4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
4.3.2 High Cost Associated With the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Cancer Type
5.1.1 Endometrial Adenocarcinoma
5.1.2 Adenosquamous Carcinoma
5.1.3 Papillary Serous Carcinoma
5.1.4 Uterine Sarcoma
5.2 By Product
5.2.1 Therapeutics Surgery Immunotherapy Radiation Therapy Chemotherapy Other Therapeutics
5.2.2 Diagnostics Biopsy Pelvic Ultrasound Hysteroscopy Dilation and Curettage CT Scan
5.3 Geography
5.3.1 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
6.1 Company Profiles
6.1.1 Merck & Co., Inc
6.1.2 Eisai.Co.Ltd
6.1.3 Abbott Laboratories
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Siemens Healthcare Inc
6.1.7 GlaxoSmithKline Plc
6.1.8 Novartis AG

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co., Inc
  • Eisai.Co.Ltd
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Siemens Healthcare Inc
  • GlaxoSmithKline Plc
  • Novartis AG